---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-059656"
form_type: "8-K"
ticker: "COLL"
cik: "0001267565"
company_name: "COLLEGIUM PHARMACEUTICAL, INC"
filed_at: "2024-05-10T23:59:59+00:00"
generated_at: "2026-06-02T03:23:54.789841+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# CEO Joseph Ciaffoni steps down; Chairman Michael Heffernan named Interim CEO

## Summary
- Joseph Ciaffoni to step down as President and CEO effective May 24, 2024.
- Ciaffoni will not stand for re-election to the Board at May 16 Annual Meeting; Board reduced from nine to eight.
- Michael Heffernan, current Chairman, appointed Interim President and CEO effective May 24, 2024.
- Heffernan to receive base salary at $291,666 annual rate (one-third of Ciaffoni's salary).
- Board has initiated a search for a permanent President and CEO.

## SEC filing metadata
- accession: 0001104659-24-059656
- form_type: 8-K
- ticker: COLL
- cik: 0001267565
- company_name: COLLEGIUM PHARMACEUTICAL, INC
- filed_at: 2024-05-10T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1267565/000110465924059656/0001104659-24-059656-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1267565/000110465924059656/tm2414016d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-059656
- JSON: https://secwatch.observer/filing/0001104659-24-059656.json
- Plain text: https://secwatch.observer/filing/0001104659-24-059656.txt

## Key facts
- Executive change
  Joseph Ciaffoni departed as President and Chief Executive Officer at COLLEGIUM PHARMACEUTICAL, INC.
  - Action: stepped down
  - Role: President and Chief Executive Officer
  source text: announced that Joseph Ciaffoni will step down as the President and Chief Executive Officer of Collegium Pharmaceutical, Inc. (the “Company”) effective May 24, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1267565/000110465924059656/0001104659-24-059656-index.htm
- Executive change
  Michael Heffernan was appointed as Interim President and Chief Executive Officer at COLLEGIUM PHARMACEUTICAL, INC.
  - Action: appointed
  - Role: Interim President and Chief Executive Officer
  source text: the Board approved the appointment of Michael Heffernan, the Company’s Chairman of the Board, to Interim President and Chief Executive Officer, effective May 24, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1267565/000110465924059656/0001104659-24-059656-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.